Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway — Telix Pharmaceuticals Limited

Event summary

Telix completed enrollment of 350 patients in the Phase 3 BiPASS study for prostate cancer imaging.
The study evaluates the diagnostic performance of 68Ga-PSMA-PET combined with MRI for detecting prostate cancer prior to biopsy.
Telix aligned with the FDA on a New Drug Application (NDA) pathway for BiPASS, which could support reimbursement and broaden patient access.
BiPASS builds on the PRIMARY and PRIMARY2 studies, which demonstrated significant improvements in diagnostic accuracy and reduction of unnecessary biopsies.

The big picture

Telix's completion of the Phase 3 BiPASS study and alignment with the FDA on the NDA pathway represent a strategic shift in prostate cancer diagnostics. The study aims to establish precision imaging as a critical step in initial diagnosis, potentially reducing the need for biopsies and improving patient outcomes. This development aligns with broader industry trends towards more accurate and non-invasive diagnostic methods, which could lower healthcare costs and enhance treatment decisions.

What we're watching

Regulatory Approval: Whether the FDA will approve the NDA pathway for BiPASS, which could significantly expand the market for 68Ga-PSMA-PET imaging.
Market Expansion: The pace at which Telix can broaden access to 68Ga-PSMA-PET imaging across a larger patient population if BiPASS meets its primary objectives.
Clinical Impact: How the combination of MRI and PSMA-PET/CT with Telix’s proprietary agents will affect diagnostic accuracy and reduce unnecessary biopsies.